|Mr. Yat-Gai Au||Founder, Chairman & CEO||N/A||N/A||1973|
|Ms. Michelle Chan||Financial Controller||N/A||N/A||N/A|
|Mr. Wai Hong Chung||COO & Chief Strategy Officer||N/A||N/A||1977|
|Mr. Tien Hsiang Chau||Exec. Officer||N/A||N/A||1970|
|Ms. Antonia Assang||Sr. VP of Project Management||N/A||N/A||N/A|
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Regencell Bioscience Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.